ClinicalTrials.gg
CompletedNCT01084863CompareUpdated Jan 24, 2025Results posted

Evaluate Safety, Efficacy and Pharmacokinetics

A Phase 1/2 interventional study of CT-P6 and Herceptin in Metastatic Breast Cancer, sponsored by Celltrion. Completed at 1 site in Korea, Republic of. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Celltrion · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.

Enrollment
316th of 505
143 · median 218
Started
2010
with 21 others
Phase 1/2
55 of 618
17 open now
Registered
84th of 618
by date

Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 316th largest by enrollment of the 505 interventional ones that give a count, is one of 22 that started in 2010, is one of 55 in phase 1/2, and was the 84th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

127 more — sign in →

All 132 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 618 studies in Breast Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)

Read the detailed description

Patients will receive CT-P6 or Herceptin.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Herceptin
  • Her 2-positive
  • metastatic breast cancer
  • CT-P6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are females
  • Have a Her 2 over-expression
  • Have (ECOG) 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Current clinical or radiographic evidence central nervous system (CNS)
  • Current Known infection
  • Pregnant or nursing mother
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    CT-P6 & Paclitaxel

    CT-P6 was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death, or discontinuation. Paclitaxel was administered at a dose of 175 mg/m2 body surface area (BSA) as a continuous 3-hour IV infusion on the day following the first dose of study drug (CT-P6). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death, intolerable toxicity, or discontinuation.

    Drug: CT-P6 · Drug: Paclitaxel

  • Active comparator
    Herceptin & Paclitaxel

    Herceptin was administered at a loading dose of 8 mg/kg body weight by IV infusion over 90 minutes on Day 1, Cycle 1, then at 6 mg/kg repeated at 3-weekly intervals until disease progression, death, or discontinuation. Paclitaxel was administered at a dose of 175 mg/m2 body surface area (BSA) as a continuous 3-hour IV infusion on the day following the first dose of study drug (Herceptin). If the first dose of study drug was well tolerated, subsequent doses of paclitaxel were given immediately after the next dose of study drug. Paclitaxel cycles were repeated every 3 weeks until disease progression, death, intolerable toxicity, or discontinuation.

    Drug: Herceptin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve at Steady State (AUCss)

    Area under the concentration time curve at steady state (AUCss), defined as area under the concentration-time curve between Cycle 8 to Cycle 9. The primary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).

    Time frame: 3, 6, 12, 24, 72, 168, 336, 504 hours predose

Secondary outcomes

  1. Trough Concentration at Steady State (CtroughSS)

    Trough concentration at steady state (CtroughSS), defined as trough concentration at steady state. The secondary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).

    Time frame: 3, 6, 12, 24, 72, 168, 336, 504 hours predose

  2. Cardiotoxicity

    Cardiac Ejection Fraction Assessment, defined as Mean change from baseline to endpoint assessment in left ventricular ejection fraction (LVEF, Unit: %) from the independent tumor review committee (ITRC).

    Time frame: Up to approximately 1 year

  3. Immunogenicity

    Immunogenicity, defined as proportion of patients with antibodies to study drug (positive for antidrug antibody \[ADA\] result after the first study infusion).

    Time frame: every 4 cycles (each cycle is 3 weeks), Up to approximately 5.5 years

  4. Overall Response Rate (ORR; Complete Response [CR] Plus Partial Response [PR]) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Overall response rate (ORR) based on best overall response (BOR) during the Main Study Treatment Period and up to 1-year treatment from the independent tumor review committee (ITRC) and Investigator. ORR (complete response \[CR\] plus partial response \[PR\]), as assessed by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 To be assigned a best ORR of PR or CR, changes in tumour assessments must be confirmed no less than 4 weeks after the criteria for response were met.

    Time frame: every 6 weeks (up to cycle 4) or 12 weeks (after cycle 4) (every cycle is 3 weeks), up to 6 months in Main treatment period and up to 1 year

  5. Serum Human Epidermal Growth Factor Receptor-2 (HER-2) Shed Antigen Value

    Serum Human epidermal growth factor receptor-2 (HER-2) shed antigen values at baseline (Cycle 1, Day 1) and the last assessments.

    Time frame: day 1 of each cycle (every cycle is 3 weeks), Up to approximately 5.5 years

07

Results

Posted Jan 24, 2025

Participant flow

Main Study Treatment Period
Participant flow — Main Study Treatment Period
MilestoneCT-P6 & PaclitaxelHerceptin & Paclitaxel
Started7667
Completed6056
Not completed1611
Withdrew: Disease progression117
Withdrew: Adverse event53
Withdrew: Other reason01
Treatment Period Beyond Cycle 8
Participant flow — Treatment Period Beyond Cycle 8
MilestoneCT-P6 & PaclitaxelHerceptin & Paclitaxel
Started6056
Completed00
Not completed6056
Withdrew: Withdrawal by subject44
Withdrew: Physician decision24
Withdrew: Disease progression5145
Withdrew: Adverse event10
Withdrew: Other01
Withdrew: Other reason22

Outcome measures

PrimaryArea Under the Concentration Time Curve at Steady State (AUCss)

Area under the concentration time curve at steady state (AUCss), defined as area under the concentration-time curve between Cycle 8 to Cycle 9. The primary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).

Time frame:
3, 6, 12, 24, 72, 168, 336, 504 hours predose
Reported as:
Mean · ug*h/mL
Area Under the Concentration Time Curve at Steady State (AUCss)
ug*h/mLCT-P6 & PaclitaxelHerceptin & Paclitaxel
Area Under the Concentration Time Curve at Steady State (AUCss)34400 ± 1500031800 ± 9820
Statistical analysis
  • CT-P6 & Paclitaxel vs Herceptin & Paclitaxel · Geometric mean ratio: 104.57 · 90% CI 93.64 to 116.78
SecondaryTrough Concentration at Steady State (CtroughSS)

Trough concentration at steady state (CtroughSS), defined as trough concentration at steady state. The secondary endpoint was reached at 6 months (8 treatment cycle; Main Study Treatment Period).

Time frame:
3, 6, 12, 24, 72, 168, 336, 504 hours predose
Reported as:
Mean · ug/mL
Trough Concentration at Steady State (CtroughSS)
ug/mLCT-P6 & PaclitaxelHerceptin & Paclitaxel
Trough Concentration at Steady State (CtroughSS)21.1 ± 7.8320.8 ± 8.26
SecondaryCardiotoxicity

Cardiac Ejection Fraction Assessment, defined as Mean change from baseline to endpoint assessment in left ventricular ejection fraction (LVEF, Unit: %) from the independent tumor review committee (ITRC).

Time frame:
Up to approximately 1 year
Reported as:
Mean · %; percentage of LVEF
Cardiotoxicity
%; percentage of LVEFCT-P6 & PaclitaxelHerceptin & Paclitaxel
Cardiotoxicity-5.49 ± 6.543-6.43 ± 5.622
SecondaryImmunogenicity

Immunogenicity, defined as proportion of patients with antibodies to study drug (positive for antidrug antibody \[ADA\] result after the first study infusion).

Time frame:
every 4 cycles (each cycle is 3 weeks), Up to approximately 5.5 years
Reported as:
Count of participants · Participants
Immunogenicity
ParticipantsCT-P6 & PaclitaxelHerceptin & Paclitaxel
Immunogenicity20
SecondaryOverall Response Rate (ORR; Complete Response [CR] Plus Partial Response [PR]) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Overall response rate (ORR) based on best overall response (BOR) during the Main Study Treatment Period and up to 1-year treatment from the independent tumor review committee (ITRC) and Investigator. ORR (complete response \[CR\] plus partial response \[PR\]), as assessed by Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 To be assigned a best ORR of PR or CR, changes in tumour assessments must be confirmed no less than 4 weeks after the criteria for response were met.

Time frame:
every 6 weeks (up to cycle 4) or 12 weeks (after cycle 4) (every cycle is 3 weeks), up to 6 months in Main treatment period and up to 1 year
Reported as:
Number · percentage of responder
Overall Response Rate (ORR; Complete Response [CR] Plus Partial Response [PR]) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of responderCT-P6 & Paclitaxel ITRCHerceptin & Paclitaxel ITRCCT-P6 & Paclitaxel InvestigatorHerceptin & Paclitaxel Investigator
Main Study Treatment Period61.876.168.480.6
1 Year65.877.672.480.6
SecondarySerum Human Epidermal Growth Factor Receptor-2 (HER-2) Shed Antigen Value

Serum Human epidermal growth factor receptor-2 (HER-2) shed antigen values at baseline (Cycle 1, Day 1) and the last assessments.

Time frame:
day 1 of each cycle (every cycle is 3 weeks), Up to approximately 5.5 years
Reported as:
Mean · ng/mL
Serum Human Epidermal Growth Factor Receptor-2 (HER-2) Shed Antigen Value
ng/mLCT-P6 & PaclitaxelHerceptin & Paclitaxel
Baseline (Cycle 1, Day 1)85.20 ± 195.1077.87 ± 169.14
Last assessment49.68 ± 162.108.82 ± 19.97

Adverse events

Collected over Adverse event (AE) reporting extended from the date of informed consent until completion of the final visit. (Up to approximately 170 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CT-P6 & Paclitaxel2/76 (2.6%)12/76 (15.8%)74/76 (97.4%)
Herceptin & Paclitaxel3/67 (4.5%)19/67 (28.4%)64/67 (95.5%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCT-P6 & PaclitaxelHerceptin & Paclitaxel
Disease progressionGeneral disorders1/765/67
Febrile neutropeniaBlood and lymphatic system disorders2/763/67
NeutropeniaBlood and lymphatic system disorders0/763/67
BacteraemiaInfections and infestations2/760/67
Back painMusculoskeletal and connective tissue disorders0/761/67
Biliary drainageSurgical and medical procedures0/761/67
Brain oedemaNervous system disorders0/761/67
Cardiac failure acuteCardiac disorders0/761/67
CholangitisHepatobiliary disorders0/761/67
Cholecystitis acuteHepatobiliary disorders0/761/67
Most frequent other events
Showing 10 of 49
Most frequent other events
EventCT-P6 & PaclitaxelHerceptin & Paclitaxel
AlopeciaSkin and subcutaneous tissue disorders47/7644/67
NeutropeniaBlood and lymphatic system disorders32/7633/67
MyalgiaMusculoskeletal and connective tissue disorders31/7631/67
Peripheral sensory neuropathyNervous system disorders21/7627/67
AstheniaGeneral disorders24/7610/67
Neuropathy peripheralNervous system disorders23/7621/67
DiarrhoeaGastrointestinal disorders13/7618/67
NauseaGastrointestinal disorders19/7617/67
Pain in extremityMusculoskeletal and connective tissue disorders10/7617/67
ArthralgiaMusculoskeletal and connective tissue disorders10/7615/67

Baseline characteristics

The Full Analysis Set (FAS) was defined as all randomized patients who received any study drug (CT-P6 or Herceptin) and had at least one post-baseline assessment, with the exception of the patients who violated against Herceptin indication.

Age, Categorical
Age, Categorical(Participants)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
<=18 years000
Between 18 and 65 years6359122
>=65 years13821
Age, Continuous
Age, Continuous(years)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
Mean55.1 ± 10.2653.6 ± 10.4754.4 ± 10.35
Sex: Female, Male
Sex: Female, Male(Participants)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
Female7667143
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
White453580
Asian313263
Region of Enrollment
Region of Enrollment(Participants)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
Bulgaria628
South Korea313263
Latvia7613
Russia191635
Serbia459
Ukraine9615
Childbearing potential
Childbearing potential(Participants)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
Yes182442
No5843101
Height at Screening
Height at Screening(cm)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
Mean158.9 ± 6.70160.3 ± 7.20159.6 ± 6.95
Weight at Screening
Weight at Screening(kg)CT-P6 & PaclitaxelHerceptin & PaclitaxelTotal
Mean66.0 ± 16.6467.6 ± 15.7166.7 ± 16.17

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Dec 2011, 22 months.

Results were first posted in Jan 2025, 13 years 1 month after primary completion.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 22 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2010
First posted
Mar 11, 2010
StartActual
Feb 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2023
Results first posted
Jan 24, 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01084863
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Mar 11, 2010
Start date
Feb 2010
Primary completion
Dec 2011
Completion
Dec 2023
Results posted
Jan 24, 2025
Last update
Jan 24, 2025

Study contacts

Investigational Site
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CT-P6

Start the discussion